Diligence memo · auto-generated · as of July 3, 2026
Illuminare Biotechnologies Inc
Illuminare Biotechnologies Inc looks over-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Illuminare Biotechnologies Inc operates in Biotechnology, based in BROOKLYN.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Illuminare Biotechnologies Inc has raised $4.9M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).
Largest single filing: $2.5M on 2018-12-17.
Most recent recorded round closed around 2018-12-17.
Valuation (modeled)modeled
Provath models Illuminare Biotechnologies Inc at approximately $111M (range $1.8M–$871M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 1.56× the median modeled value of Seed Biotechnology companies in 2016–2018 (175 peers) — value vs value, same stage and era. Issuer reports no revenue, yet is modeled well above niche peers.
Financing rhythm & timingmixed
Historic cadence: a new round about every 16 months.
Last raise 7.5 yr ago; this sector typically re-raises about every 14 months.
Silent for over 3× the sector's normal cadence.
The last round stepped up 1.1× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 43% of Biotechnology peers (4293 compared).
Modeled value ranks above 61% of those peers.
Closest niche peers: Mimedx Group, Inc., Kenjockety Biotechnology, LLC, Helocyte, Inc., CytoDel, INC., Finch Therapeutics, Inc..
Peoplefiled
4 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.